Analysis: The FDA’s Plans To Reduce Drug Prices Through Increased Competition Must Be Bolstered

Today, the Commonwealth Fund published an issue brief cataloging and analyzing the actions of Commissioner Scott Gottlieb and the US Food and Drug Administration (FDA) to increase price competition for prescription drugs as a means to address high prescription drug prices.

Prescription drug prices have reached an all-time high, creating barriers to access and treatment for patients around the country. FDA Commissioner Gottlieb has taken on the issue indirectly, and announced several actions by the FDA intended to increase generic drug competition and transparency.

While the FDA has made strides in implementing some of their policy and operational announcements, there is still much more work to be done. The FDA’s broad authority over drug approvals gives the agency authority to take additional actions beyond what has been proposed. Furthermore, there is an opportunity for Congress to further support increased competition and address anti-competitive behaviors given the high public interest in tackling high prescription drug prices.

Check out the issue brief here.

Real Change

Seize the moment. Send the message. Solve the problem. With Waxman, it’s all possible.

See Our Work